Glenmark initiates Ph 3 trials on Favipiravir for COVID-19 in India
India, May 13 -- Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, has initiated Phase 3 clinical trials inIndiaon Antiviral tablet Favipiravir, for which it received approval from India's drug regulator DCGI in late April.
Glenmark is the first company inIndiato initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients inIndia. Favipiravir is a generic version of Avigan(R) of Fujifilm Toyama Chemical Co. Ltd.,Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals inIndiaare being enrolled for the study. Glenmark estimates study completion by July/August 2020.
Glenmark has successfully developed the API and the formulatio...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.